

# The R.E.D. Tools: Advances in RESP and ESP charge derivation and force field library building

June 23, 2010

François-Yves Dupradeau,<sup>1,\*</sup> Adrien Pigache,<sup>1</sup> Thomas Zaffran,<sup>1</sup> Corentin Savineau,<sup>1</sup> Rodolphe  
Lelong,<sup>1</sup> Nicolas Grivel,<sup>1</sup> Dimitri Lelong,<sup>1</sup> Wilfried Rosanski,<sup>1</sup> Piotr Cieplak<sup>2,\*</sup>

<sup>1</sup> CNRS UMR 6219 & UFR de Pharmacie, Université de Picardie - Jules Verne, 1, rue des Louvels, F-80037 Amiens cedex  
1, France.

<sup>2</sup> Sanford|Burnham Institute for Medical Research, La Jolla, California, 92037, USA.

**To whom correspondence should be addressed:** François-Yves Dupradeau, Tel: +33-(0)3-2282-7498, Fax: +33-(0)3-2282-  
7469, e-mail: fyd@q4md-forcefieldtools.org; or Piotr Cieplak, Tel: +1-858-646-3100, Fax: +1-858-713-9949, e-mail:  
pcieplak@burnham.org

**(A)**

```
REMARK TITLE Ethanol
REMARK CHARGE-VALUE 0
REMARK MULTIPLICITY-VALUE 1
REMARK
REMARK REORIENT 1 5 8 | 8 5 1
REMARK
ATOM      1  CT1  EOH      1      1.218  -0.218  -0.000      C1
ATOM      2  H1   EOH      1      2.059   0.469  -0.000      H11
ATOM      3  H1   EOH      1      1.287  -0.849   0.879      H12
ATOM      4  H1   EOH      1      1.287  -0.849  -0.879      H13
ATOM      5  CT2  EOH      1     -0.092   0.543   0.000      C2
ATOM      6  H2   EOH      1     -0.152   1.184   0.878      H21
ATOM      7  H2   EOH      1     -0.152   1.184  -0.878      H22
ATOM      8  O3   EOH      1     -1.139  -0.394   0.000      O3
ATOM      9  H3   EOH      1     -1.971   0.058  -0.000      H3
CONNECT   1    2    3    4    5
CONNECT   2    1
CONNECT   3    1
CONNECT   4    1
CONNECT   5    1    6    7    8
CONNECT   6    5
CONNECT   7    5
CONNECT   8    5    9
CONNECT   9    8
END
```

**(B)**

```
REMARK TITLE g,g_Dimethylphosphate
REMARK CHARGE-VALUE -1
REMARK MULTIPLICITY-VALUE 1
REMARK
REMARK REORIENT 1 6 10 | 10 6 1 | 7 6 8 | 8 6 7
REMARK
REMARK INTER-MCC 0.0 | 1 2 | 10 11 12 13 | 1 2
REMARK INTER-MCC 0.0 | 1 2 | 1 2 3 4 | 3 4
REMARK
REMARK INTER-MEQA 2 3 4 5 | 1 2 3 4 7 8 9 10 11 12 13 14 15 16 17
REMARK
ATOM      1  C1  DMP      1      1.100   0.000   0.000      C1
ATOM      2  H11 DMP      1      0.000   0.000   0.000      H11
ATOM      3  H12 DMP      1      1.476   1.034   0.000      H12
ATOM      4  H13 DMP      1      1.476  -0.484   0.913      H13
ATOM      5  O2  DMP      1      1.524  -0.687  -1.135      O3'
ATOM      6  P3  DMP      1      3.138  -0.847  -1.398      P
ATOM      7  O4  DMP      1      3.811   0.378  -0.942      O1P
ATOM      8  O4  DMP      1      3.281  -1.435  -2.738      O2P
ATOM      9  O6  DMP      1      3.475  -2.001  -0.280      O5'
ATOM     10  C7  DMP      1      3.096  -3.315  -0.544      C2
ATOM     11  H71 DMP      1      2.018  -3.403  -0.661      H21
ATOM     12  H72 DMP      1      3.568  -3.689  -1.444      H22
ATOM     13  H73 DMP      1      3.401  -3.925   0.302      H23
CONNECT   1    2    3    4    5
CONNECT   2    1
CONNECT   3    1
CONNECT   4    1
CONNECT   5    1    6
CONNECT   6    5    7    8    9
CONNECT   7    6
CONNECT   8    6
CONNECT   9    6   10
CONNECT  10    9   11   12   13
CONNECT  11   10
CONNECT  12   10
CONNECT  13   10
END
```

(c1)

```
REMARK TITLE O-methyl-tyrosine-dipeptide
REMARK CHARGE-VALUE 0
REMARK MULTIPLICITY-VALUE 1
REMARK
REMARK REORIENT 5 11 12 | 12 11 5 | 6 12 31 | 31 12 6
REMARK
REMARK conformation close to that found in an alpha-helix structure
ATOM      1  CT1  ACE      1      -5.084  -1.603  -0.248      C1
ATOM      2  H1   ACE      1      -4.983  -2.676  -0.108      H11
ATOM      3  H1   ACE      1      -5.962  -1.270   0.287      H12
ATOM      4  H1   ACE      1      -5.206  -1.410  -1.308      H13
ATOM      5  C2   ACE      1      -3.867  -0.910   0.325       C
ATOM      6  O3   ACE      1      -3.846  -0.454   1.432       O
ATOM      7  N4   TYM      2      -2.788  -0.838  -0.506       N
ATOM      8  H4   TYM      2      -2.817  -1.380  -1.341       H
ATOM      9  C5   TYM      2      -1.474  -0.461  -0.004      CA
ATOM     10  H5   TYM      2      -1.267  -0.984   0.919      HA
ATOM     11  C6   TYM      2      -1.377   1.027   0.346       C
ATOM     12  O7   TYM      2      -0.642   1.399   1.215       O
ATOM     13  CT8  TYM      2      -0.430  -0.846  -1.074      CB
ATOM     14  H8   TYM      2      -0.614  -1.883  -1.343     HB1
ATOM     15  H8   TYM      2      -0.614  -0.254  -1.966     HB2
ATOM     16  C9   TYM      2       1.015  -0.703  -0.652      CG
ATOM     17  C100 TYM      2       1.773   0.391  -1.021     CD1
ATOM     18  H100 TYM      2       1.329   1.172  -1.614     HD1
ATOM     19  C100 TYM      2       1.633  -1.689   0.117     CD2
ATOM     20  H100 TYM      2       1.073  -2.559   0.418     HD2
ATOM     21  C111 TYM      2       3.105   0.521  -0.643     CE1
ATOM     22  H111 TYM      2       3.652   1.390  -0.951     HE1
ATOM     23  C111 TYM      2       2.948  -1.579   0.503     CE2
ATOM     24  H111 TYM      2       3.421  -2.340   1.096     HE2
ATOM     25  C14   TYM      2       3.697  -0.466   0.125      CZ
ATOM     26  O15   TYM      2       4.978  -0.448   0.547      OZ
ATOM     27  CT16 TYM      2       5.784   0.658   0.261      CM
ATOM     28  H16   TYM      2       6.742   0.460   0.719     HM1
ATOM     29  H16   TYM      2       5.370   1.569   0.681     HM2
ATOM     30  H16   TYM      2       5.921   0.785  -0.808     HM3
ATOM     31  N17   NME      3      -2.081   1.873  -0.442       N
ATOM     32  H17   NME      3      -2.830   1.482  -0.965       H
ATOM     33  CT18 NME      3      -2.150   3.283  -0.119      C2
ATOM     34  H18   NME      3      -1.152   3.669   0.027     H21
ATOM     35  H18   NME      3      -2.722   3.465   0.785     H22
ATOM     36  H18   NME      3      -2.614   3.808  -0.944     H23
CONNECT    1    2    3    4    5
CONNECT    2    1
CONNECT    3    1
CONNECT    4    1
CONNECT    5    1    6    7
CONNECT    6    5
CONNECT    7    5    8    9
CONNECT    8    7
CONNECT    9    7   10   11   13
CONNECT   10    9
CONNECT   11    9   12   31
CONNECT   12   11
CONNECT   13    9   14   15   16
CONNECT   14   13
CONNECT   15   13
CONNECT   16   13   17   19
CONNECT   17   16   18   21
CONNECT   18   17
```

To be continued on the next page...

```

CONNECT 19 16 20 23
CONNECT 20 19
CONNECT 21 17 22 25
CONNECT 22 21
CONNECT 23 19 24 25
CONNECT 24 23
CONNECT 25 21 23 26
CONNECT 26 25 27
CONNECT 27 26 28 29 30
CONNECT 28 27
CONNECT 29 27
CONNECT 30 27
CONNECT 31 11 32 33
CONNECT 32 31
CONNECT 33 31 34 35 36
CONNECT 34 33
CONNECT 35 33
CONNECT 36 33

```

TER

REMARK conformation close to that found in an beta-sheet structure

```

ATOM 1 CT1 ACE 1 -0.937 3.565 0.075 C1
ATOM 2 H1 ACE 1 0.045 3.673 0.526 H11
ATOM 3 H1 ACE 1 -1.034 4.295 -0.715 H12
ATOM 4 H1 ACE 1 -1.684 3.750 0.839 H13
ATOM 5 C2 ACE 1 -1.048 2.179 -0.521 C
ATOM 6 O3 ACE 1 -0.766 1.955 -1.667 O
ATOM 7 N4 TYM 2 -1.444 1.214 0.346 N
ATOM 8 H4 TYM 2 -1.825 1.476 1.228 H
ATOM 9 C5 TYM 2 -1.636 -0.160 -0.047 CA
ATOM 10 H5 TYM 2 -1.392 -0.221 -1.096 HA
ATOM 11 C6 TYM 2 -3.093 -0.538 0.205 C
ATOM 12 O7 TYM 2 -3.641 -0.216 1.228 O
ATOM 13 CT8 TYM 2 -0.735 -1.124 0.754 CB
ATOM 14 H8 TYM 2 -1.002 -1.044 1.802 HB1
ATOM 15 H8 TYM 2 -0.973 -2.140 0.450 HB2
ATOM 16 C9 TYM 2 0.744 -0.865 0.574 CG
ATOM 17 C100 TYM 2 1.424 -1.325 -0.540 CD1
ATOM 18 H100 TYM 2 0.897 -1.889 -1.292 HD1
ATOM 19 C100 TYM 2 1.473 -0.148 1.520 CD2
ATOM 20 H100 TYM 2 0.980 0.219 2.403 HD2
ATOM 21 C111 TYM 2 2.779 -1.084 -0.727 CE1
ATOM 22 H111 TYM 2 3.260 -1.461 -1.608 HE1
ATOM 23 C111 TYM 2 2.818 0.101 1.356 CE2
ATOM 24 H111 TYM 2 3.377 0.652 2.090 HE2
ATOM 25 C14 TYM 2 3.483 -0.365 0.225 CZ
ATOM 26 O15 TYM 2 4.799 -0.074 0.151 OZ
ATOM 27 CT16 TYM 2 5.535 -0.480 -0.966 CM
ATOM 28 H16 TYM 2 6.543 -0.124 -0.809 HM1
ATOM 29 H16 TYM 2 5.142 -0.046 -1.880 HM2
ATOM 30 H16 TYM 2 5.552 -1.561 -1.060 HM3
ATOM 31 N17 NME 3 -3.687 -1.285 -0.744 N
ATOM 32 H17 NME 3 -3.237 -1.377 -1.625 H
ATOM 33 CT18 NME 3 -5.073 -1.692 -0.634 C2
ATOM 34 H18 NME 3 -5.751 -0.864 -0.807 H21
ATOM 35 H18 NME 3 -5.257 -2.085 0.355 H22
ATOM 36 H18 NME 3 -5.267 -2.467 -1.363 H23
END

```

(C2)

```

REMARK TITLE O-methyl-tyrosine-dipeptide
REMARK CHARGE-VALUE 0
REMARK MULTIPLICITY-VALUE 1
REMARK
REMARK REORIENT 5 11 12 | 12 11 5 | 6 12 31 | 31 12 6
REMARK
REMARK INTRA-MCC 0.0 | 1 2 3 4 5 6 | R
REMARK INTRA-MCC 0.0 | 31 32 33 34 35 36 | R
REMARK INTRA-MCC -.4157 | 7 | K
REMARK INTRA-MCC .2719 | 8 | K
REMARK INTRA-MCC .5973 | 11 | K
REMARK INTRA-MCC -.5679 | 12 | K
REMARK
REMARK conformation close to that found in an alpha-helix structure
ATOM      1  C1  ACE      1      -5.084 -1.603 -0.248      C1
ATOM      2  H11 ACE      1      -4.983 -2.676 -0.108      H11
ATOM      3  H12 ACE      1      -5.962 -1.270  0.287      H12
ATOM      4  H13 ACE      1      -5.206 -1.410 -1.308      H13
ATOM      5  C2  ACE      1      -3.867 -0.910  0.325       C
ATOM      6  O3  ACE      1      -3.846 -0.454  1.432       O
ATOM      7  N4  TYM      2      -2.788 -0.838 -0.506       N
ATOM      8  H4  TYM      2      -2.817 -1.380 -1.341       H
ATOM      9  C5  TYM      2      -1.474 -0.461 -0.004       CA
ATOM     10  H5  TYM      2      -1.267 -0.984  0.919       HA
ATOM     11  C6  TYM      2      -1.377  1.027  0.346       C
ATOM     12  O7  TYM      2      -0.642  1.399  1.215       O
ATOM     13  CT8 TYM      2      -0.430 -0.846 -1.074       CB
ATOM     14  H8  TYM      2      -0.614 -1.883 -1.343      HB1
ATOM     15  H8  TYM      2      -0.614 -0.254 -1.966      HB2
ATOM     16  C9  TYM      2       1.015 -0.703 -0.652      CG
ATOM     17  C100 TYM     2       1.773  0.391 -1.021     CD1
ATOM     18  H100 TYM     2       1.329  1.172 -1.614     HD1
ATOM     19  C100 TYM     2       1.633 -1.689  0.117     CD2
ATOM     20  H100 TYM     2       1.073 -2.559  0.418     HD2
ATOM     21  C111 TYM     2       3.105  0.521 -0.643     CE1
ATOM     22  H111 TYM     2       3.652  1.390 -0.951     HE1
ATOM     23  C111 TYM     2       2.948 -1.579  0.503     CE2
ATOM     24  H111 TYM     2       3.421 -2.340  1.096     HE2
ATOM     25  C14  TYM     2       3.697 -0.466  0.125      CZ
ATOM     26  O15  TYM     2       4.978 -0.448  0.547      OZ
ATOM     27  CT16 TYM     2       5.784  0.658  0.261      CM
ATOM     28  H16  TYM     2       6.742  0.460  0.719     HM1
ATOM     29  H16  TYM     2       5.370  1.569  0.681     HM2
ATOM     30  H16  TYM     2       5.921  0.785 -0.808     HM3
ATOM     31  N17  NME     3      -2.081  1.873 -0.442       N
ATOM     32  H17  NME     3      -2.830  1.482 -0.965       H
ATOM     33  C18  NME     3      -2.150  3.283 -0.119       C2
ATOM     34  H181 NME     3      -1.152  3.669  0.027      H21
ATOM     35  H182 NME     3      -2.722  3.465  0.785      H22
ATOM     36  H183 NME     3      -2.614  3.808 -0.944      H23
CONNECT   1    2    3    4    5
CONNECT   2    1
CONNECT   3    1
CONNECT   4    1
CONNECT   5    1    6    7
CONNECT   6    5
CONNECT   7    5    8    9
CONNECT   8    7
CONNECT   9    7   10   11   13
CONNECT  10    9
CONNECT  11    9   12   31
    
```

```

CONNECT 12 11
CONNECT 13 9 14 15 16
CONNECT 14 13
CONNECT 15 13
CONNECT 16 13 17 19
CONNECT 17 16 18 21
CONNECT 18 17
CONNECT 19 16 20 23
CONNECT 20 19
CONNECT 21 17 22 25
CONNECT 22 21
CONNECT 23 19 24 25
CONNECT 24 23
CONNECT 25 21 23 26
CONNECT 26 25 27
CONNECT 27 26 28 29 30
CONNECT 28 27
CONNECT 29 27
CONNECT 30 27
CONNECT 31 11 32 33
CONNECT 32 31
CONNECT 33 31 34 35 36
CONNECT 34 33
CONNECT 35 33
CONNECT 36 33

```

TER

REMARK conformation close to that found in an beta-sheet structure

```


ATOM 1 C1 ACE 1 -0.937 3.565 0.075 C1
ATOM 2 H11 ACE 1 0.045 3.673 0.526 H11
ATOM 3 H12 ACE 1 -1.034 4.295 -0.715 H12
ATOM 4 H13 ACE 1 -1.684 3.750 0.839 H13
ATOM 5 C2 ACE 1 -1.048 2.179 -0.521 C
ATOM 6 O3 ACE 1 -0.766 1.955 -1.667 O
ATOM 7 N4 TYM 2 -1.444 1.214 0.346 N
ATOM 8 H4 TYM 2 -1.825 1.476 1.228 H
ATOM 9 C5 TYM 2 -1.636 -0.160 -0.047 CA
ATOM 10 H5 TYM 2 -1.392 -0.221 -1.096 HA
ATOM 11 C6 TYM 2 -3.093 -0.538 0.205 C
ATOM 12 O7 TYM 2 -3.641 -0.216 1.228 O
ATOM 13 CT8 TYM 2 -0.735 -1.124 0.754 CB
ATOM 14 H8 TYM 2 -1.002 -1.044 1.802 HB1
ATOM 15 H8 TYM 2 -0.973 -2.140 0.450 HB2
ATOM 16 C9 TYM 2 0.744 -0.865 0.574 CG
ATOM 17 C100 TYM 2 1.424 -1.325 -0.540 CD1
ATOM 18 H100 TYM 2 0.897 -1.889 -1.292 HD1
ATOM 19 C100 TYM 2 1.473 -0.148 1.520 CD2
ATOM 20 H100 TYM 2 0.980 0.219 2.403 HD2
ATOM 21 C111 TYM 2 2.779 -1.084 -0.727 CE1
ATOM 22 H111 TYM 2 3.260 -1.461 -1.608 HE1
ATOM 23 C111 TYM 2 2.818 0.101 1.356 CE2
ATOM 24 H111 TYM 2 3.377 0.652 2.090 HE2
ATOM 25 C14 TYM 2 3.483 -0.365 0.225 CZ
ATOM 26 O15 TYM 2 4.799 -0.074 0.151 OZ
ATOM 27 CT16 TYM 2 5.535 -0.480 -0.966 CM
ATOM 28 H16 TYM 2 6.543 -0.124 -0.809 HM1
ATOM 29 H16 TYM 2 5.142 -0.046 -1.880 HM2
ATOM 30 H16 TYM 2 5.552 -1.561 -1.060 HM3
ATOM 31 N17 NME 3 -3.687 -1.285 -0.744 N
ATOM 32 H17 NME 3 -3.237 -1.377 -1.625 H
ATOM 33 C18 NME 3 -5.073 -1.692 -0.634 C2
ATOM 34 H181 NME 3 -5.751 -0.864 -0.807 H21
ATOM 35 H182 NME 3 -5.257 -2.085 0.355 H22
ATOM 36 H183 NME 3 -5.267 -2.467 -1.363 H23

```

END

**Figure S1.** Examples of P2N input files used by the R.E.D. program. (A) P2N input file used in charge derivation of the ethanol molecule (two molecular orientations and a single molecule conformation). (B) P2N input file used in charge derivation of the dimethylphosphate molecule (four molecular orientations and a single molecule conformation) involved in the FFTopDB building for deoxyribonucleic acid. (C1) P2N input file used in charge derivation of the *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide (four molecular orientations and two molecule conformations). (C2) P2N input file used in charge derivation of the central fragment of *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide (four molecular orientations and two molecular conformations). Detailed descriptions of the P2N file format associated with the R.E.D. Tools is available in a specific tutorial.<sup>64</sup>





**Figure S2.** Screen snapshot of the X R.E.D. graphical interface.

Molecule	Proc. <sup>(a)</sup>	QMP. <sup>(b)</sup>	Step 1 <sup>(c)</sup>	Step 2 <sup>(d)</sup>	Step 2	Step 2	Step 3 <sup>(e)</sup>	R.E.D.D.B.
name			T.L. <sup>(f)</sup>	T.L.	Surf. <sup>(g)</sup>	R.A. <sup>(h)</sup>	Fit <sup>(i)</sup>	code <sup>(j)</sup>
Dimethylsulfoxide	1 conf - 1 orient	GAMESS	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-1
Dimethylsulfoxide	1 conf - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-2
Dimethylsulfoxide	1 conf - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-3
Dimethylsulfoxide	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-4
Ethanol	1 conf <sup>(a1)</sup> - 1 orient	GAMESS	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-5
Ethanol	1 conf <sup>(a1)</sup> - 1 orient	GAMESS	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-6
Ethanol	1 conf <sup>(a1)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-7
Ethanol	1 conf <sup>(a1)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-8
Ethanol	1 conf <sup>(a1)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-9
Ethanol	2 conf <sup>(a2)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-10
Dimethylphosphate	1 conf <sup>(a3)</sup> - 1 orient	GAMESS	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-11
Dimethylphosphate	1 conf <sup>(a3)</sup> - 1 orient	GAMESS	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-12
Dimethylphosphate	1 conf <sup>(a3)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-13
Dimethylphosphate	1 conf <sup>(a3)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	QMRA	2 RESP stg	W-14
Trifluoroethanol	1 conf <sup>(a1)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-15
Trifluoroethanol	2 conf <sup>(a2)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-16
Methoxyethane	1 conf <sup>(a1)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-17
Methoxyethane	1 conf <sup>(a4)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-18
Methoxyethane	2 conf <sup>(a2)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-19
<i>N</i> -Methylacetamide	1 conf <sup>(a5)</sup> - 2 orient	g98	B3LYP/6-311++G**	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-20
<i>N</i> -Methylacetamide	1 conf <sup>(a6)</sup> - 2 orient	g98	B3LYP/6-311++G**	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-21
<i>N</i> -Methylacetamide	2 conf <sup>(a7)</sup> - 4 orient	g98	B3LYP/6-311++G**	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-22
1,4-Dioxane	1 conf <sup>(a8)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-23
1,4-Dioxane	1 conf <sup>(a9)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-24
1,4-Dioxane	2 conf <sup>(a10)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-25
Ethane-1,2-diol	1 conf <sup>(a11)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-26
Ethane-1,2-diol	1 conf <sup>(a12)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-27
Ethane-1,2-diol	1 conf <sup>(a13)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-28
Ethane-1,2-diol	1 conf <sup>(a14)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-29
Ethane-1,2-diol	1 conf <sup>(a15)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-30
Ethane-1,2-diol	5 conf <sup>(a16)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-31

Molecule	Proc. <sup>(a)</sup>	QM P. <sup>(b)</sup>	Step 1 <sup>(c)</sup>	Step 2 <sup>(d)</sup>	Step 2	Step 2	Step 3 <sup>(e)</sup>	R.E.DD.B.
name			T.L. <sup>(f)</sup>	T.L.	Surf. <sup>(g)</sup>	R.A. <sup>(h)</sup>	Fit <sup>(i)</sup>	code <sup>(j)</sup>
Methanol	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-32
Propanone	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-33
Ethanoic acid	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-34
Acetonitrile	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-35
Formamide	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-36
Methanal	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-37
Furane	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-38
Pyrrrole	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-39
Benzene	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-40
Toluene	1 conf - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-41
Choroforme	1 conf - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-42
Cyclohexane	1 conf <sup>(a8)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-43
Cyclohexane	1 conf <sup>(a9)</sup> - 2 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-44
Cyclohexane	2 conf <sup>(a10)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-45
Organic solvent 10 molecules <sup>(m1)</sup>	1 conf - 2 & 4 orient <sup>(a17)</sup>	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-46
Organic solvent 10 molecules <sup>(m1)</sup>	1 conf - 2 & 4 orient <sup>(a17)</sup>	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	W-47
Organic solvent 10 molecules <sup>(m1)</sup>	1 conf - 2 & 4 orient <sup>(a17)</sup>	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	W-48
Organic solvent 10 molecules <sup>(m1)</sup>	1 conf - 2 ; 4 orient <sup>(a17)</sup>	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	W-49
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-50
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-51
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-52
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 1 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-53
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-54
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a18)</sup> - 10 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-55
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a19)</sup> - 10 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-56
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	1 conf <sup>(a20)</sup> - 10 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-57

Molecule	Proc. (a)	QM P. (b)	Step 1 (c)	Step 2 (d)	Step 2	Step 2	Step 3 (e)	R.E.D.D.B.
name			T.L. (f)	T.L.	Surf. (g)	R.A. (h)	Fit (i)	code (j)
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	3 conf (a21)- 10 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-58
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	3 conf (a21)- 10 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	W-59
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	3 conf (a21)- 10 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	W-60
<i>N</i> -ACE- <i>L</i> -ALA- <i>N'</i> -NME	3 conf (a21)- 10 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	W-61
Deoxyadenosine	1 conf (a22)- 12 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-62
Deoxyadenosine	1 conf (a23)- 12 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-63
Deoxyadenosine	2 conf (a24)- 12 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-64
Deoxyadenosine	2 conf (a24)- 12 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	W-65
Deoxyadenosine	2 conf (a24)- 12 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	W-66
Deoxyadenosine	2 conf (a24)- 12 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	W-67
Deoxyadenosine	2 conf (a24)- 12 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	1 RESP stg	W-68
DNA Nucleosides <sup>(m2)</sup> 4 molecules	2 conf (a24)- 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-69
DNA Nucleosides <sup>(m2)</sup> 4 molecules	2 conf (a24)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	W-70
DNA Nucleosides <sup>(m2)</sup> 4 molecules	2 conf (a24)- 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	W-71
DNA Nucleosides <sup>(m2)</sup> 4 molecules	2 conf (a24)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	W-72
DNA Nucleosides <sup>(m2)</sup> 4 molecules	2 conf (a24)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	1 RESP stg	W-73
RNA Nucleosides <sup>(m3)</sup> 4 molecules	1 conf (a23)- 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	W-74
RNA Nucleosides <sup>(m3)</sup> 4 molecules	1 conf (a23)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	W-75
RNA Nucleosides <sup>(m3)</sup> 4 molecules	1 conf (a23)- 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	W-76
RNA Nucleosides <sup>(m3)</sup> 4 molecules	1 conf (a23)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	W-77
RNA Nucleosides <sup>(m3)</sup> 4 molecules	1 conf (a23)- 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	1 RESP stg	W-78

Molecule	Proc. (a)	QMP. (b)	Step 1 (c)	Step 2 (d)	Step 2	Step 2	Step 3 (e)	R.E.D.D.B.
name			T.L. (f)	T.L.	Surf. (g)	R.A. (h)	Fit (i)	code (j)
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	1 conf <sup>(a25)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-1
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	1 conf <sup>(a26)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-2
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-3
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-4
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-5
<i>N</i> -ACE-AIB- <i>N'</i> -NME <sup>(m4)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-6
Methylammonium <sup>(m5)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-7
Methylammonium <sup>(m5)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-8
Methylammonium <sup>(m5)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-9
Methylammonium <sup>(m5)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-10
Ethanoate <sup>(m6)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-11
Ethanoate <sup>(m6)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-12
Ethanoate <sup>(m6)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-13
Ethanoate <sup>(m6)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-14
Methylamine <sup>(m7)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-15
Methylamine <sup>(m7)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-16
Methylamine <sup>(m7)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-17
Methylamine <sup>(m7)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-18

Molecule	Proc. <sup>(a)</sup>	QM P. <sup>(b)</sup>	Step 1 <sup>(c)</sup>	Step 2 <sup>(d)</sup>	Step 2	Step 2	Step 3 <sup>(e)</sup>	R.E.DD.B.
name			T.L. <sup>(f)</sup>	T.L.	Surf. <sup>(g)</sup>	R.A. <sup>(h)</sup>	Fit <sup>(i)</sup>	code <sup>(j)</sup>
Ethanoic acid <sup>(m8)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-19
Ethanoic acid <sup>(m8)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-20
Ethanoic acid <sup>(m8)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-21
Ethanoic acid <sup>(m8)</sup> <i>N</i> -ACE-AIB- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-22
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	1 conf <sup>(a25)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-23
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	1 conf <sup>(a26)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-24
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-25
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-26
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-27
<i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME <sup>(m9)</sup>	2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-28
Methylammonium <sup>(m10)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-29
Methylammonium <sup>(m10)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-30
Methylammonium <sup>(m10)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-31
Methylammonium <sup>(m10)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-32
Ethanoate <sup>(m11)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-33
Ethanoate <sup>(m11)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-34
Ethanoate <sup>(m11)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-35
Ethanoate <sup>(m11)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-36

Molecule	Proc. <sup>(a)</sup>	QM P. <sup>(b)</sup>	Step 1 <sup>(c)</sup>	Step 2 <sup>(d)</sup>	Step 2	Step 2	Step 3 <sup>(e)</sup>	R.E.DD.B.
name			T.L. <sup>(f)</sup>	T.L.	Surf. <sup>(g)</sup>	R.A. <sup>(h)</sup>	Fit <sup>(i)</sup>	code <sup>(j)</sup>
Methylamine <sup>(m12)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-37
Methylamine <sup>(m12)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-38
Methylamine <sup>(m12)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-39
Methylamine <sup>(m12)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-40
Ethanoic acid <sup>(m13)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-41
Ethanoic acid <sup>(m13)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-42
Ethanoic acid <sup>(m13)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-43
Ethanoic acid <sup>(m13)</sup> <i>N</i> -ACE- <i>L</i> -TYM- <i>N'</i> -NME	1 conf - 2 orient 2 conf <sup>(a27)</sup> - 4 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-44
DNA FFTopDB 5 molecules <sup>(m14)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-45
DNA FFTopDB 5 molecules <sup>(m14)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-46
DNA FFTopDB 5 molecules <sup>(m14)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-47
DNA FFTopDB 5 molecules <sup>(m14)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-48
DNA FFTopDB 5 molecules <sup>(m14)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	1 RESP stg	F-49
DNA FFTopDB 5 molecules <sup>(m15)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-50

Molecule	Proc. (a)	QM P. (b)	Step 1 (c)	Step 2 (d)	Step 2	Step 2	Step 3 (e)	R.E.D.D.B.
name			T.L. (f)	T.L.	Surf. (g)	R.A. (h)	Fit (i)	code (j)
RNA FFTopDB 5 molecules <sup>(m16)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-51
RNA FFTopDB 5 molecules <sup>(m16)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-52
RNA FFTopDB 5 molecules <sup>(m16)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	ESP	F-53
RNA FFTopDB 5 molecules <sup>(m16)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	ESP	F-54
RNA FFTopDB 5 molecules <sup>(m16)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	1 RESP stg	F-55
RNA FFTopDB 5 molecules <sup>(m17)</sup>	1 conf <sup>(a3)</sup> - 4 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-56
NA FFTopDB 9 molecules <sup>(m18)</sup>	1 conf <sup>(a3)</sup> - 4 orient 2 conf <sup>(a24)</sup> - 6 orient 1 conf <sup>(a23)</sup> - 6 orient	g98	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-60
New AA frag 18 molecules <sup>(m19)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	Connolly	RBRA	1 ESP stg	F-73
New AA frag 18 molecules <sup>(m19)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-74
New AA frag 18 molecules <sup>(m20)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-75
New AA frag 18 molecules <sup>(m21)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-76
New AA frag 18 molecules <sup>(m22)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	Connolly	RBRA	2 RESP stg	F-77
New AA frag 18 molecules <sup>(m19)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	B3LYP/cc-pVTZ	Connolly	RBRA	2 RESP stg	F-78
New AA frag 18 molecules <sup>(m20)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	B3LYP/cc-pVTZ	Connolly	RBRA	2 RESP stg	F-79
New AA frag 18 molecules <sup>(m19)</sup>	2 or 4 orient 1 and/or 2 conf <sup>(a25,a26,a27)</sup>	g03	HF/6-31G*	HF/6-31G*	CHELPG	RBRA	2 RESP stg	F-80



**Table S3.** Summary of charge derivations reported in this work, and available in R.E.DD.B.<sup>59,60,64,72</sup> Charge values were derived from charge fitting and not arithmetic mean. When not specified all-atom force field libraries were generated.

<sup>(a)</sup> Charge derivation procedures involving a fully characterized number of molecular orientation(s) and conformation(s) for each reported molecular system; conf = molecular conformation; orient = molecular orientation. <sup>(b)</sup> QM P. = QM programs used in the geometry optimization and MEP computation steps (GAMESS-US, Gaussian 98 or 03 was interfaced). <sup>(c)</sup> Step 1 = First step of the charge derivation *i. e.* geometry optimization (for each molecule *i* conformations might be considered). <sup>(d)</sup> Step 2 = Second step of the charge derivation *i. e.* MEP computation (for each molecule, *i* conformation \* *j* orientation MEP computations might be considered). <sup>(e)</sup> Step 3 = Third and last step of the charge derivation *i. e.* charge fitting. <sup>(f)</sup> T.L. = QM theory levels used in Steps 1 and 2. <sup>(g)</sup> Surface or grid algorithms on which is computed each MEP (the Connolly surface and CHELPG algorithms were both used). <sup>(h)</sup> R.A. = Re-orientation algorithm applied before MEP computation; both QMRA and RBRA approaches were used. <sup>(i)</sup> Fit = Charge fitting approach carried out in Step 3; 2 RESP stg = 2 stage RESP fitting; 1 RESP stg = 1 stage RESP fitting; ESP = 1 stage ESP fitting. <sup>(j)</sup> R.E.DD.B. code. <sup>(a1)</sup> = *anti* conformation. <sup>(a2)</sup> = *anti* and *gauche+* conformations. <sup>(a3)</sup> = *gauche+*, *gauche+* conformation. <sup>(a4)</sup> = *gauche+* conformation. <sup>(a5)</sup> = *cis* conformation. <sup>(a6)</sup> = *trans* conformation. <sup>(a7)</sup> = *cis* and *trans* conformations. <sup>(a8)</sup> = *chair* conformation. <sup>(a9)</sup> = *twist-boat* conformation. <sup>(a10)</sup> = *chair* and *twist-boat* conformations. <sup>(a11)</sup> = *anti anti anti* conformation. <sup>(a12)</sup> = *anti gauche+ anti* conformation. <sup>(a13)</sup> = *gauche+ anti gauche-* conformation. <sup>(a14)</sup> = *gauche+ gauche- gauche+* conformation. <sup>(a15)</sup> = *gauche+ gauche+ gauche+* conformation. <sup>(a16)</sup> = *anti anti anti, anti gauche+ anti, gauche+ anti gauche-, gauche+ gauche- gauche+, gauche+ gauche+ gauche+* conformations. <sup>(a17)</sup> 2 or 4 molecular orientations were used in the charge derivation. <sup>(a18)</sup> = *C5* conformation. <sup>(a19)</sup> = *C7ax* conformation. <sup>(a20)</sup> = *C7eq* conformation. <sup>(a21)</sup> = *C5, C7ax* and *C7eq* conformations. <sup>(a22)</sup> = *C2'endo* conformation. <sup>(a23)</sup> = *C3'endo* conformation. <sup>(a24)</sup> = *C2'endo* and *C3'endo* conformations. <sup>(a25)</sup> = conformation close to the alpha helix form. <sup>(a26)</sup> = conformation close to the extended form. <sup>(a27)</sup> = conformations close to the alpha helix and extended forms. <sup>(m1)</sup> = Charge derivation involving 10 solvent molecules (Dimethylsulfoxide, Ethanol, Trifluoroethanol, Methanol, Acetone, Acetic acid, Acetonitrile, Benzene, Toluene and Chloroform). <sup>(m2)</sup> = Charge derivation involving the 4 regular DNA nucleosides (Deoxyadenosine, Deoxycytidine, Deoxyguanosine and Deoxythymidine). <sup>(m3)</sup> = Charge derivation involving the 4 regular RNA nucleosides (Adenosine, Cytidine, Guanosine and Uridine). <sup>(m4)</sup> = Charge derivation of the central fragment of alpha-aminoisobutyric acid. <sup>(m5)</sup> = Charge derivation of the *N*-terminal charged fragment of alpha-aminoisobutyric acid. <sup>(m6)</sup> = Charge derivation of the *C*-terminal charged fragment of alpha-aminoisobutyric acid. <sup>(m7)</sup> = Charge derivation of the *N*-terminal neutral fragment of alpha-aminoisobutyric acid. <sup>(m8)</sup> = Charge derivation of the *C*-terminal neutral fragment of alpha-aminoisobutyric acid. <sup>(m9)</sup> = Charge derivation of the central fragment of *O*-methyl-*L*-tyrosine. <sup>(m10)</sup> = Charge derivation of the *N*-terminal charged fragment of *O*-methyl-*L*-tyrosine. <sup>(m11)</sup> = Charge derivation of the *C*-terminal charged fragment of *O*-methyl-*L*-tyrosine. <sup>(m12)</sup> = Charge derivation of the *N*-terminal neutral fragment of *O*-methyl-*L*-tyrosine. <sup>(m13)</sup> = Charge derivation of the *C*-terminal neutral fragment of *O*-methyl-*L*-tyrosine. <sup>(m14)</sup> = FFTopDB constituted of 16 molecular fragments for deoxyribonucleic acid based on a charge derivation involving the 5 DNA nucleosides and dimethylphosphate. <sup>(m15)</sup> = FFTopDB constituted of 16 molecular fragments for deoxyribonucleic acid based on a charge derivation involving

the 5 DNA nucleosides and dimethylphosphate (fragment topology differs in the phosphate connection). <sup>(m16)</sup> = FFTopDB constituted of 16 molecular fragments ribonucleic acid based on a charge derivation involving the 5 RNA nucleosides and dimethylphosphate. <sup>(m17)</sup> = FFTopDB constituted of 16 molecular fragments for ribonucleic acid based on a charge derivation involving the 5 RNA nucleosides and dimethylphosphate (fragment topology differs in the phosphate connection). <sup>(m18)</sup> = FFTopDB constituted of 32 molecular fragments for nucleic acids based on a charge derivation involving 9 molecules (the regular DNA and RNA nucleosides and dimethylphosphate). <sup>(m19)</sup> = Simultaneous charge derivation of the central, *N*-terminal and *C*-terminal fragment of *O*-methyl-*L*-tyrosine and the *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide involving 18 molecules. <sup>(m20)</sup> = Simultaneous charge derivation of the central, *N*-terminal and *C*-terminal fragment of *O*-methyl-*L*-tyrosine and the *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide involving 18 molecules. United-methylene and methyl carbon force field libraries were generated by setting to a value of zero the charge value of each selected hydrogen atom during the charge fitting step, and by removing the corresponding hydrogen(s) from each force field library. <sup>(m21)</sup> = Simultaneous charge derivation of the central, *N*-terminal and *C*-terminal fragment of *O*-methyl-*L*-tyrosine and the *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide involving 18 molecules. United-carbon force field libraries were generated by summing the charge values of each hydrogen within the charge value of the carbon they are bound to *a posteriori* to the charge fitting step, and by removing the corresponding hydrogen(s) from each force field library. <sup>(m22)</sup> = Simultaneous charge derivation of the central, *N*-terminal and *C*-terminal fragment of *O*-methyl-*L*-tyrosine and the *N*-acetyl-*O*-methyl-*L*-tyrosine-*N'*-methylamide dipeptide involving 18 molecules. United-methylene and methyl carbon force field libraries were generated by summing the charge values of each hydrogen within the charge value of the carbon they are bound to *a posteriori* to the charge fitting step, and by removing the corresponding hydrogen(s) from each force field library.

<b>Orient.nb</b> <sup>(a)</sup>	<b>-A-</b>	<b>-B-</b>	<b>-C-</b>	<b>-D-</b>	<b>MCVD</b>	<b>-A-</b>	<b>-B-</b>	<b>-C-</b>	<b>-D-</b>	<b>MCVD</b>
<b>Surf</b> <sup>(b)</sup>	<b>CS</b>	<b>CS</b>	<b>CS</b>	<b>CS</b>	<b>CS</b>	<b>CG</b>	<b>CG</b>	<b>CG</b>	<b>CG</b>	<b>CG</b>
<b>ACE-C1</b>	-0.6678	-0.6661	-0.6902	-0.7098	0.044	-0.4875	-0.4998	-0.4841	-0.4835	0.016
<b>ACE-H11</b>	0.1805	0.1783	0.1857	0.1902	-	0.1301	0.1333	0.1288	0.1293	-
<b>ACE-H12</b>	= H11	= H11	= H11	= H11	-	= H11	= H11	= H11	= H11	-
<b>ACE-H13</b>	= H11	= H11	= H11	= H11	-	= H11	= H11	= H11	= H11	-
<b>ACE-C</b>	0.8574	0.8792	0.8736	0.8878	0.030	0.8819	0.8823	0.8841	0.8720	0.012
<b>ACE-O</b>	-0.6257	-0.6284	-0.6281	-0.6303	0.005	-0.6425	-0.6410	-0.6426	-0.6388	0.004
<b>ALA-N</b>	-0.6149	-0.6313	-0.6312	-0.6489	0.034	-0.7077	-0.7021	-0.7147	-0.6936	0.021
<b>ALA-H</b>	0.2920	0.3022	0.2938	0.3010	-	0.3084	0.3086	0.3103	0.3056	-
<b>ALA-CA</b>	0.2248	0.1467	0.2402	0.2448	0.098	0.2583	0.2430	0.2725	0.2437	0.030
<b>ALA-HA</b>	0.0111	0.0289	0.0021	0.0017	-	-0.0033	0.0002	-0.0094	-0.0018	-
<b>ALA-CB</b>	-0.2202	-0.1583	-0.1862	-0.1825	0.062	-0.1064	-0.1173	-0.1033	-0.0987	0.019
<b>ALA-HB1</b>	0.0669	0.0536	0.0564	0.0548	-	0.0331	0.0369	0.0313	0.0315	-
<b>ALA-HB2</b>	= HB1	= HB1	= HB1	= HB1	-	= HB1	= HB1	= HB1	= HB1	-
<b>ALA-HB3</b>	= HB1	= HB1	= HB1	= HB1	-	= HB1	= HB1	= HB1	= HB1	-
<b>ALA-C</b>	0.5651	0.6250	0.5707	0.5799	0.060	0.6519	0.6629	0.6509	0.6520	0.012
<b>ALA-O</b>	-0.5347	-0.5510	-0.5367	-0.5420	0.016	-0.5665	-0.5682	-0.5675	-0.5660	0.002
<b>NME-N</b>	-0.4918	-0.5054	-0.5231	-0.5118	0.031	-0.6298	-0.6325	-0.6260	-0.6263	0.007
<b>NME-H</b>	0.3289	0.3256	0.3345	0.3298	-	0.3369	0.3415	0.3385	0.3386	-
<b>NME-C2</b>	-0.2853	-0.2477	-0.1954	-0.2320	0.090	0.0568	0.0264	0.0288	0.0478	0.030
<b>NME-H21</b>	0.1396	0.1283	0.1165	0.1258	-	0.0533	0.0618	0.0608	0.0554	-
<b>NME-H22</b>	= H21	= H21	= H21	= H21	-	= H21	= H21	= H21	= H21	-
<b>NME-H23</b>	= H21	= H21	= H21	= H21	-	= H21	= H21	= H21	= H21	-
<b>MEP.pts</b> <sup>(c)</sup>	975	991	992	1017	-	14209	14169	14150	14176	-
<b>RRMS</b> <sup>(d)</sup>	0.092	0.098	0.097	0.095	-	0.130	0.126	0.130	0.130	-

**Table S4.** ESP charge derivation and force field library building for the C5 conformation of the alanine dipeptide automatically carried out using the R.E.D. Tools. Charge values were derived from charge fitting and not arithmetic mean. <sup>(a)</sup> -i- Accurate geometry optimization, -ii- molecular orientation of the optimized geometry controlled by the RBRA approach implemented in the R.E.D. program. The molecular orientation (named “-A-”, “-B-”, “-C-”, and “-D-”) are these reported in Table 4. Each of these orientations was involved in a single orientation ESP fit. The charges reported (charge reproducibility +/- 0.0001 e) were obtained using the Gaussian 03 program for both the geometry optimization and MEP computation steps. MCDV: Maximum charge value difference. <sup>(b)</sup> The Connolly surface or CHELPG algorithm was used in MEP computation,

while charge equivalencing for chemically equivalent atoms was carried out during charge fitting.<sup>(c)</sup> Number of MEP point generated for the given molecular orientations.<sup>(d)</sup> The RRMS values calculated for the fitting stage were taken directly from the outputs of the RESP program.

## References

- [59] P. Cieplak, W. D. Cornell, C. I. Bayly and P. A. Kollman, *J. Comput. Chem.* 1995, **16**, 1357-1377.
- [60] F.-Y. Dupradeau, C. Cézard, R. Lelong, E. Stanislawiak, J. Pêcher, J. C. Delepine and P. Cieplak, *Nucl. Acids Res. (Database issue)* 2008, **36**, D360-D367.
- [64] F.-Y. Dupradeau and P. Cieplak, *RESP charge derivation using the Ante\_R.E.D.-1.x & R.E.D. III.x programs*, Université de Picardie - Jules Verne. Sanford|Burnham Institute for Medical Research, 2007, <http://q4md-forcefieldtools.org/Tutorial/Tutorial-1.php>.
- [72] A. Pigache, P. Cieplak and F.-Y. Dupradeau, Automatic and highly reproducible RESP and ESP charge derivation: Application to the development of programs R.E.D. and X R.E.D., *227th ACS National Meeting*, Anaheim, CA, USA, March 28 - April 1, 2004.